



EXECUTIVE OFFICE OF HEALTH AND HUMAN SERVICES  
**COMMONWEALTH OF MASSACHUSETTS**  
OFFICE OF MEDICAID  
ONE ASHBURTON PLACE, BOSTON, MA 02108



**MAURA T. HEALEY**  
GOVERNOR

**KATHLEEN E. WALSH**  
SECRETARY

**KIMBERLEY DRISCOLL**  
LIEUTENANT GOVERNOR

**MIKE LEVINE**  
ASSISTANT SECRETARY  
FOR MASSHEALTH

April 18, 2023

Chair Michael J. Rodrigues  
Senate Committee on Ways and Means  
State House, Room 212  
Boston, MA 02133

Chair Aaron Michlewitz  
House Committee on Ways and Means  
State House, Room 243  
Boston, MA 02133

Chair Cindy F. Friedman  
Joint Committee on Health Care Financing  
State House, Room 313  
Boston, MA 02133

Chair John Lawn, Jr.  
Joint Committee on Health Care Financing  
State House, Room 236  
Boston, MA 02133

Dear Chairs Rodrigues, Michlewitz, Friedman, and Lawn:

Chapter 126 of the Acts of 2022 line item 4000-0300 requires the Executive Office of Health and Human Services to submit a quarterly report including the projected total costs for the next fiscal year of pharmaceutical pipeline drugs identified by the executive office and expected to be made available for utilization within a 12-month period.

The Executive Office of Health and Human Services has identified 84 new pipeline market entries from 78 manufacturers expected to be made available for utilization between October 1<sup>st</sup>, 2023 and September 30<sup>th</sup>, 2024. The estimated spend on the expected utilization of these products for all MassHealth members (including those enrolled with managed care) is approximately \$15.6M for the same time period. Approximately eighty percent of spend is due the anticipated utilization of two gene therapies for sickle cell disease. The prior quarterly report estimated a spend of \$17.8M based on the addition of 122 new pipeline market entries from 106 manufacturers. The reduction in spend is due to the change in anticipated market availability or approval dates of several medications.

I am grateful for your continued support of the MassHealth program. Please contact Sarah Nordberg at [Sarah.Nordberg@mass.gov](mailto:Sarah.Nordberg@mass.gov) should you have any questions about this report.

Sincerely,

Mike Levine

cc: Kathleen E. Walsh